Rare diseases
Investigational molecules
Locations
Discontinuation of methotrexate (drug combination) in rheumatoid arthritis patients using TNF inhibitors
The NetherlandsRituximab and venetoclax treatment for 6 vs 26 cycles in patients with relapsed or refractory chronic lymphocytic leukemia
The NetherlandsSafety and Efficacy of Efimosfermin Alfa in Participants with Biopsy‑Confirmed F2‑ or F3‑Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)
The NetherlandsPhase IIb Randomized, Double‑Blind Study of GIA632 in Adults with Nonsegmental Vitiligo
The NetherlandsSafety, Tolerability, Pharmacokinetics and Pharmacodynamics of DNL952 in Adults with Late‑Onset Pompe Disease
The NetherlandsA Phase 3b Study of Guselkumab Compared with Risankizumab in Adults with Moderately to Severely Active Crohn’s Disease
The NetherlandsINCA33890 With Standard Chemotherapy and Bevacizumab in First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
The NetherlandsDurvalumab and Chemotherapy in Adults With Muscle-Invasive Bladder Cancer
The NetherlandsJNJ-79635322 versus Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma After at Least 3 Prior Treatments
The NetherlandsObrixtamig, Carboplatin, and Etoposide for First-Line Treatment of Advanced Extrapulmonary Neuroendocrine Carcinoma in DLL3-Positive Patients
The NetherlandsA Study of BI 764532, Atezolizumab, Carboplatin, and Etoposide in Patients With Extensive-Stage Small Cell Lung Cancer
The NetherlandsEvaluation of pembrolizumab and bevacizumab in patients with metastatic cervical cancer
The NetherlandsTell us about your condition – we search every trial in Europe and connect you with the right site.
